Diary - News
All news Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics
New partnership to advance Nosopharm’s lead candidate to clinical stage and develop second drug candidate
NOSO-502 could be first novel antibiotic class against Enterobacteriace infections to enter clinics in forty years
Lyon, France and Hamburg, Germany, July 3, 2019 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and Evotec SE, a drug discovery and development company, today announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a secondgeneration Odilorhabdin drug candidate. Financial terms of the agreement were not disclosed.
